Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
| Status: | Completed |
|---|---|
| Conditions: | Podiatry |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 1/25/2018 |
| Start Date: | March 2004 |
| End Date: | April 2004 |
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine
tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under
fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence
crossover design.
tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under
fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence
crossover design.
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening.
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to terbinafine or any comparable or similar
product.
We found this trial at
1
site
Click here to add this to my saved trials
